Sumit K. Subudhi, MD, PhD

CAR T-Cell Therapy in Metastatic CRPC and Future Directions in Care

Rana R. McKay, MD, University of California San Diego Medical Center;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

August 29th 2023

Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.

Ongoing Clinical Trials in the Metastatic CRPC Setting

Rana R. McKay, MD, University of California San Diego Medical Center;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

August 29th 2023

Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.

Potential for CDK4/6 Inhibitors in Metastatic CRPC

Rana R. McKay, MD, University of California San Diego Medical Center;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

August 22nd 2023

Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.

Novel Therapeutic Targets in Metastatic CRPC

Rana R. McKay, MD, University of California San Diego Medical Center;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

August 22nd 2023

A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.

Metastatic CRPC: Novel Treatment Strategies With Radioligand Therapy

Rana R. McKay, MD, University of California, San Diego;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

August 15th 2023

Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.

Radioligands in the Treatment of Metastatic CRPC: Radium-223

Rana R. McKay, MD, University of California, San Diego;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

August 15th 2023

Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.

Radioligands in the Treatment of Metastatic CRPC: Lutetium-177–PSMA-617

Rana R. McKay, MD, University of California, San Diego;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

August 8th 2023

Focused discussion on the role of lutetium-177–PSMA-617 as radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Combination PARPi Strategies in Metastatic CRPC: Interpreting Data From Clinical Trials

Rana R. McKay, MD, University of California, San Diego;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

August 8th 2023

Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.

Advent of PARP Inhibitors in Metastatic CRPC

Rana R. McKay, MD, University of California, San Diego;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

August 1st 2023

Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.

Evolving Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer

Rana R. McKay, MD, University of California, San Diego;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

August 1st 2023

Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.

Informing Systemic Therapy Selection With Negative Data in HSPC

Rana R. McKay, MD, University of California, San Diego;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

July 25th 2023

A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.

What is the Role of Locoregional Therapy in Metastatic HSPC?

Rana R. McKay, MD, University of California, San Diego;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

July 25th 2023

Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.

Systemic Treatment Armamentarium in Metastatic HSPC

Rana R. McKay, MD, University of California San Diego Medical Center;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

June 26th 2023

Shared insight on the range of systemic therapy options available to patients who present with metastatic hormone-sensitive prostate cancer.

Overview of Metastatic HSPC: Diagnosis and Risk Stratification

Rana R. McKay, MD, University of California San Diego Medical Center;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD;Arash Rezazadeh Kalebasty, MD

June 26th 2023

Opening their first module on metastatic hormone-sensitive prostate cancer, panelists consider optimal diagnostic and risk stratification strategies for when a patient presents in clinic.

Dr. Subudhi on the Integration of Antiandrogen Agents in mHSPC

Sumit K. Subudhi, MD, PhD

October 21st 2021

Sumit K. Subudhi, MD, PhD, discusses the integration of antiandrogen agents in metastatic hormone-sensitive prostate cancer.

Dr. Subudhi on Future Directions With Immunotherapy in Prostate Cancer

Sumit K. Subudhi, MD, PhD

October 18th 2021

Sumit K. Subudhi, MD, PhD, discusses future directions with immunotherapy in prostate cancer.

Dr. Subudhi Discusses Rationale for CheckMate-650 Study in Prostate Cancer

Sumit K. Subudhi, MD, PhD

February 21st 2019

Sumit K. Subudhi, MD, PhD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rationale for the CheckMate-650 study in the treatment of patients with metastatic castration-resistant prostate cancer.

Sumit K. Subudhi, MD, PhD

Articles

Latest Updated Articles

Latest Conference Coverage